About the Company
impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
70
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMPL News
Impel Pharmaceuticals Inc. (IMPLQ)
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings ...
Earnings Outlook For Impel Pharmaceuticals
Impel Pharmaceuticals (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Friday, 2023-05-12. Here's what investors need to know before the announcement.
IPI Legacy Liquidation Co., Formerly Known as Impel Pharmaceuticals, Announces Confirmation and Effective Date of Joint Plan of Liquidation
SEATTLE, April 5, 2024 /PRNewswire/ -- IPI Legacy Liquidation Co., formerly known as Impel Pharmaceuticals Inc., ("Impel") and its affiliate, Impel NeuroPharma Australia PTY LTD, (together with ...
Adrian Adams's Net Worth
Adrian Adams has an estimated net worth of $3.88 Million. This is based on reported shares across multiple companies, which include NEUROLOGIX INC/DE, NEUROCRINE BIOSCIENCES INC, IMPEL ...
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares fell 21.3% to $12.76 following a report suggesting FDA staff concluded Intercept Pharmaceuticals' OCA can cause significant drug-induced liver ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
Madrigal Pharmaceuticals, Inc. (MDGL)
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday ...
RCKT Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
IPI Legacy Liquidation Co., Formerly Known as Impel Pharmaceuticals, Announces Confirmation and Effective Date of Joint Plan of Liquidation
2024 /PRNewswire/ -- IPI Legacy Liquidation Co., formerly known as Impel Pharmaceuticals Inc., ("Impel") and its affiliate, Impel NeuroPharma Australia PTY LTD, (together with Impel, the "Debtors") ...
Loading the latest forecasts...